 |
 | |
 |  |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
Bit late, but may help to track trend. Today, threee disapointent. ABGX CML for GVHD: Message 18594050 LJPC: La Jolla Pharmaceutical Announces Results of Phase III Trial of Riquent(TM) Tuesday February 18, 7:31 am ET SAN DIEGO, Feb. 18 /PRNewswire-FirstCall/ -- La Jolla Pharmaceutical Company (Nasdaq: LJPC - News) today announced preliminary findings from a Phase III clinical trial evaluating Riquent(TM), previously known as LJP 394, for the treatment of lupus renal disease. The Company continues to analyze the results from the trial. ADVERTISEMENT The objective of the study was to determine Riquent's ability to delay the following: renal flare, treatment with HDCC (high-dose corticosteroids and/or cyclophosphamide) or other immunosuppressive drugs, hospitalization, or death due to lupus (Major SLE flare); reduce antibodies to double-stranded DNA (dsDNA); and to assess safety compared with placebo in the intent-to-treat population and in patients with impaired renal function at baseline. The intent-to-treat population was defined as patients with high-affinity antibodies to Riquent. The trial was designed to compare the effect of drug or placebo treatment in two well-balanced groups of lupus patients with a history of renal disease. Additional information follows in the section titled Trial Design. Summary of Results Intent-to-treat analysis: Riquent appeared to be well tolerated with no apparent differences in the overall incidence of serious adverse events or adverse events between Riquent-treated and placebo-treated patients. However, an initial assessment of the trial data indicates that treatment with Riquent did not increase length of time to renal flare, the primary endpoint, in a statistically significant manner when compared with placebo through the end of the study. There were 298 patients in the intent-to-treat population, 145 on Riquent and 153 on placebo. Patients were treated for as long as 92 weeks with a median of 46 weeks.<snip> and NicOx: UPDATE 2-AstraZeneca, NicOx pain drug fails key test Tue February 18, 2003 07:21 AM ET (Adds NicOx downgrades, further analyst comments)By Ben Hirschler, European Pharmaceuticals Correspondent LONDON, Feb 18 (Reuters) - A new pain drug designed to cause fewer ulcers than conventional medicines failed to show significant benefits in a key clinical test, developer AstraZeneca Plc AZN.L said on Tuesday. The drug, known by the codename AZD3582 and licensed from French firm NicOx | ||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2026 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |